Annals of Oncology Advance Access published online on May 24, 2007
Annals of Oncology, doi:10.1093/annonc/mdm128
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)
1 Division of Medical Oncology, Second University, Napoli
2 Department of Medical Oncology, Istituto Oncologico Bari
3 Department of Medical Oncology, Casa Sollievo della Sofferenza Hospital, S. Giovanni Rotondo
4 Department of Surgical Oncology, Second University, Napoli
5 Unit of Surgical Oncology, Istituto Oncologico Bari
6 Department of Medical Oncology, A.O.R.N. Cardarelli, Napoli
7 Department of Medical Oncology, Potenza
8 Department of Medical Oncology, Campobasso
9 Department of Medical Oncology, Palermo, Italy
* Correspondence to: Dr F. De Vita, Division of Medical Oncology, "F. Magrassi & A. Lanzara" Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Naples, Italy, c/o II Policlinico-Via S. Pansini, 5 80131- Naples, Italy. Tel: +39-081-5666713; Fax: +39-081-5666728; E-mail: fernandodevita{at}yahoo.it
Background: This randomized, multicenter, phase III trial evaluated the efficacy and safety of the combination of epirubicin, leucovorin, 5-fluorouracil and etoposide (ELFE regimen) as adjuvant therapy for radically resected gastric cancer patients.
Patients and methods: From June 1996 to June 2001, 228 stage IB–IIIB gastric cancer patients were enrolled. All patients received a total or subtotal gastrectomy with at least a D1 lymphoadenectomy and were randomly assigned to receive surgery alone or surgery followed by chemotherapy.
Results: A total number of 630 cycles was delivered with a median number of 5. With a median follow-up of 60 months, the 5-year overall survival (OS) was 48% in the treatment arm and 43.5% in the control arm [hazard ratio (HR) 0.91; 95% confidence interval (CI) 0.69–1.21; P = 0.610); the 5-year disease-free survival (DFS) was 44% in the treatment arm and 39% in the control arm (HR 0.88; 95% CI 0.78–0.91; P = 0.305). In node-positive patients, the 5-year OS was 41% in the treatment arm and 34% in the control arm (HR 0.84; 95% CI 0.69–1.01; P = 0.068), while the 5-year DFS was 39% in the treatment arm and 31% in the control arm (HR 0.88; 95% CI 0.78–0.91; P = 0.051). The most common grade 3–4 toxic effects according to World Health Organization criteria were hematological and gastrointestinal.
Conclusions: In radically resected gastric cancer patients, adjuvant chemotherapy with ELFE regimen does not improve OS over surgery alone.
adjuvant chemotherapy, ELFE regimen, gastric cancer
Received for publication January 8, 2007. Revision received March 7, 2007. Accepted for publication March 8, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Di Costanzo, S. Gasperoni, L. Manzione, G. Bisagni, R. Labianca, S. Bravi, E. Cortesi, P. Carlini, R. Bracci, S. Tomao, et al. Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC J Natl Cancer Inst, March 19, 2008; 100(6): 388 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Wu and J. Ji Adjuvant Chemotherapy for Gastric Cancer or Not: A Dilemma? J Natl Cancer Inst, March 19, 2008; 100(6): 376 - 377. [Full Text] [PDF]
|
|